What are the side effects of taking Ghrelin Mimetic?
The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain. http://www.annals.org/cgi/content/full/149/9/601 Sapphire Therapeutics, Inc., a private biopharmaceutical company that inlicenses compounds acting within the ghrelin pathway and develops them as treatments for metabolic and oncologic diseases, has licensed a highly potent and selective small-molecule ghrelin mimetic, ipamorelin, from Novo Nordisk. The first indication for which Sapphire is developing ipamorelin is postoperative ileus (POI), the slowing or stopping of intestinal movement that frequently occurs after surgery. Ipamorelin has already demonstrated a good safety and tolerability profile in Phase I clinical studies conducted by Novo Nordisk. No financial terms of the licensing arrangement were disclosed.
The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain. http://www.annals.org/cgi/content/full/149/9/601 Sapphire Therapeutics, Inc., a private biopharmaceutical company that inlicenses compounds acting within the ghrelin pathway and develops them as treatments for metabolic and oncologic diseases, has licensed a highly potent and selective small-molecule ghrelin mimetic, ipamorelin, from Novo Nordisk. The first indication for which Sapphire is developing ipamorelin is postoperative ileus (POI), the slowing or stopping of intestinal movement that frequently occurs after surgery. Ipamorelin has already demonstrated a good safety and tolerability profile in Phase I clinical studies conducted by Novo Nordisk. No financial terms of the licensing arrangement were disclosed.
